Theranexus (EPA:ALTHX) | WebDisclosure

PRESS RELEASE

published on 04/23/2024 at 07:30, 7 months 28 days ago

Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030

Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project
PRESS RELEASE

published on 04/23/2024 at 07:30, 7 months 28 days ago

Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO

Theranexus Diverchim ARNA Laboratory Autophagy Activation Therapy PickASO
BRIEF

published on 04/18/2024 at 18:05, 8 months 3 days ago

Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study

Clinical Study Rare Diseases Theranexus Batten-1 Batten Disease CLN3
BRIEF

published on 04/18/2024 at 18:05, 8 months 3 days ago

Theranexus et BBDF annoncent des résultats positifs pour l'étude de phase 1/2 de Batten-1

Étude Clinique Maladies Rares Theranexus Maladie De Batten CLN3 Batten-1
PRESS RELEASE

published on 04/18/2024 at 18:00, 8 months 3 days ago

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults

Theranexus Batten-1 BBDF Juvenile Batten Disease Phase I/II Trial
PRESS RELEASE

published on 04/18/2024 at 18:00, 8 months 3 days ago

Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2
Theranexus et la Fondation BBDF annoncent des données positives sur la stabilisation des symptômes moteurs chez les patients jeunes adultes atteints de la maladie de Batten CLN3 après 18 mois de traitement

Theranexus Fondation BBDF Maladie De Batten Stabilisation Symptômes Moteurs Traitement Batten-1
PRESS RELEASE

published on 05/10/2023 at 16:59, 1 year 7 months ago

Theranexus et BBDF obtiennent l'accord de la FDA sur les critères d'efficacité de l'étude de phase 3 de Batten-1 dans la maladie de Batten CLN3

Published on 12/21/2024 at 01:30, 16 hours 40 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 16 hours 40 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 5 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 18 hours 10 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 18 hours 40 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 17 hours 18 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 17 hours 25 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 22 hours 59 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 14 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 5 hours 52 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 5 hours 52 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 1 day ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE

News